TriNetX Becomes the Leading Source of Real-World Data in Peer-Reviewed Publications

TriNetX: Leading the Charge in Real-World Data Utilization for Health Research

In a remarkable stride for real-world evidence (RWE) in healthcare, TriNetX has been declared the most-cited source of electronic health record (EHR) data in peer-reviewed research. According to a recent analysis of PubMed data, TriNetX has surpassed its competitors with over 2,000 citations, marking an increase of nearly 80% year-over-year. This surge demonstrates a significant shift in how clinical researchers, health authorities, and organizations worldwide are approaching real-world evidence in medical research.

With a staggering 2,025 citations noted by August 27, 2025, TriNetX’s usage is approximately 1,300% higher than its closest competitor, which has only 149 citations. This growing reliance on TriNetX illustrates its pivotal role in supporting high-impact medical publications, especially in notable journals such as Nature Medicine, The Journal of Allergy and Clinical Immunology, and JAMIA Open.

The analysis highlights not just the quantity of citations but also the qualitative shift in research focus, where more investigators are integrating TriNetX data into their studies. From just 96 citations in 2021 to 707 in 2024, the trend is climbing, with a remarkable 952 citations achieved within the first eight months of 2025 alone. If the current pace continues, TriNetX is poised to exceed 1,000 citations in a single year for the first time.

Dr. Jeffrey Brown, Chief Scientific Officer at TriNetX, articulated the trust that researchers place in the data derived from their platform. He stated, "Researchers must be able to rely on the data they employ to endure peer review and produce meaningful insights. The fact that TriNetX is now the most frequently cited data source from practice reflects our scale and quality, as well as the confidence that the global research community has in our platform to advance science and improve patient outcomes.”

TriNetX is not only expanding in citations but also in its operational capacity. Its global network, TriNetX LIVE™, has seen explosive growth in participating health organizations and patient data. From September 2024 to September 2025, record numbers were documented, particularly in emerging markets; regions like Latin America recorded a 70% increase, while the Asia-Pacific area saw a 31% growth in contributions.

Reflecting on this expansion, Steve Kundrot, Chief Operating Officer of TriNetX, noted, "The accelerated growth of our network mirrors the global interests of our clients and network partners, encompassing everything from drug research to study design and comparative effectiveness analyses.” This rapid onboarding of healthcare organizations is further reinforcing the reliability of real-world evidence.

Simultaneously, the studies that leverage TriNetX data are pivotal in establishing new standards for how RWD influences clinical drug and vaccine development, the generation of clinical evidence, safety, efficacy in practice, and patient care outcomes. TriNetX enables an environment where researchers can efficiently improve clinical trial protocols, enhance operational workflows, refine safety signals, and enrich the generation of practical evidence.

As more healthcare institutions recognize the power and potential of RWE, TriNetX’s unmatched scale, depth, and transparency become the cornerstone for reliable research. As the narrative of real-world data evolves, the implications for clinical practices and patient care are profound and far-reaching. As TriNetX continues on this trajectory, it not only shapes the future of healthcare research but also represents a significant leap towards a data-informed practice.

For additional information on TriNetX and their offerings, visit TriNetX or follow them on LinkedIn.